Values for MCII/PASS for BASDAI/BASFI with stratified analysis. Numbers of the strata will not always add up to the total number of patients owing to missing values in the variable according to which patients are stratified. Continuous variables were stratified by the median value in their respective outcome measure: median baseline BASDAI = 4.9, median baseline BASFI = 4.6.
| Variables | BASDAI | BASFI | ||||||
|---|---|---|---|---|---|---|---|---|
| PASS | MCII | PASS | MCII | |||||
| n | Value (95% CI) | n | Value (95% CI) | n | Value (95% CI) | n | Value (95% CI) | |
| Overall cutoff values | 178 | 4.1 (3.8–4.4) | 114 | 0.7 (0.4–1.0) | 166 | 3.8 (3.5–4.1) | 96 | 0.4 (0.2–0.6) |
| Stratified analysis | ||||||||
| Women | 40 | 4.2 (3.5–4.8) | 27 | 0.5 (0.0–1.0) | 34 | 3.5 (2.7–4.3) | 25 | 0.5 (0.0–0.9) |
| Men | 136 | 4.1 (3.8–4.4) | 87 | 0.7 (0.4–1.0) | 130 | 3.8 (3.5–4.1) | 70 | 0.4 (0.1–0.7) |
| HLA-B27+ | 121 | 4.1 (3.8–4.4) | 75 | 0.6 (0.3–0.9) | 117 | 3.8 (3.4–4.2) | 57 | 0.4 (0.1–0.7) |
| HLA-B27− | 28 | 4.1 (3.5–4.7) | 15 | 0.5 (0.0–1.3) | 23 | 3.5 (3.4–4.2) | 16 | 0.7 (0.0–1.4) |
| SpA-EAM history, yes | 60 | 4.2 (3.8–4.5) | 41 | 1.0 (0.6–1.4) | 58 | 4.1 (3.6–4.6) | 35 | 0.4 (0.0–0.8) |
| SpA-EAM history, no | 107 | 4.1 (3.8–4.4) | 67 | 0.5 (0.1–0.9) | 98 | 3.6 (3.2–4.0) | 53 | 0.5 (0.1–0.9) |
| Age ≤ 41.4 yrs | 79 | 4.0 (3.6–4.4) | 53 | 0.7 (0.3–1.1) | 74 | 2.9 (2.5–3.3) | 49 | 0.4 (0.0–0.8) |
| Age > 41.4 yrs | 91 | 4.2 (3.8–4.6) | 60 | 0.5 (0.1–0.9) | 85 | 4.8 (4.3–5.3) | 46 | 0.5 (0.2–0.8) |
| Disease duration ≤ 11 yrs | 82 | 3.5 (3.1–3.9) | 52 | 0.8 (0.4–1.2) | 83 | 3.2 (2.8–3.6) | 51 | 0.5 (0.2–0.8) |
| Disease duration > 11 yrs | 89 | 4.4 (4.1–4.7) | 56 | 0.5 (0.2–0.8) | 78 | 4.5 (4.1–4.9) | 39 | 0.4 (0.0–0.8) |
| Baseline score < median | 101 | 3.1 (2.8–3.4) | 50 | 0.5 (0.2–0.8) | 102 | 2.9 (2.7–3.1) | 46 | 0.3 (0.1–0.5) |
| Baseline score ≥ median | 76 | 4.8 (4.4–5.2) | 64 | 1.2 (0.8–1.6) | 64 | 5.8 (5.2–6.4) | 50 | 0.6 (0.2–1.0) |
| Patients with baseline BASDAI ≥ 4 | 115 | 4.5 (4.2–4.8) | 88 | 1.1 (0.8–1.4) | 103 | 4.6 (4.2–5.0) | 73 | 0.6 (0.3–0.9) |
| Patients with baseline BASDAI < 4 | 62 | 2.9 (2.5–3.3) | 26 | 1.2 (0.8–1.6) | 62 | 2.5 (2.1–2.9) | 23 | 1.0 (0.6–1.4) |
MCII: minimum clinically important improvement; PASS: patient-acceptable symptom state; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; SpA-EAM: spondyloarthritis extraarticular manifestations.